Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome

8 Aug 2012

Abstract excerpt

The 8p11 myeloproliferative syndrome is a rare, aggressive myeloproliferative neoplasm characterized by constitutively active FGFR1 fusion proteins that arise from specific chromosomal translocations and which drive aberrant proliferation. Although FGFR1 inhibitors have shown in vitro activity against FGFR1 fusions, none are in use clinically and there is a need to assess additional compounds as potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22875613
DOI: 10.3324/haematol.2012.066407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromePMID 22875613Read ↗

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.Semantic proximity Read ↗

Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.Semantic proximity Read ↗

Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndromeSemantic proximity Read ↗

Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemiaSemantic proximity Read ↗

The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapySemantic proximity Read ↗

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.Semantic proximity Read ↗

The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of <i>FGFR1</i>Semantic proximity Read ↗

Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinasesSemantic proximity Read ↗

Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFRα Mutation.Semantic proximity Read ↗

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Targeting FGFR1 to suppress leukemogenesis in syndromic and <i>de novo</i> AML in murine modelsSemantic proximity Read ↗

Ponatinib in the therapy of chronic myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.